<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01306981</url>
  </required_header>
  <id_info>
    <org_study_id>BAIJ1006</org_study_id>
    <nct_id>NCT01306981</nct_id>
  </id_info>
  <brief_title>Ranibizumab in Diabetic Vitrectomy. A Prospective, Randomised Controlled Trial of Ranibizumab Pre-treatment in Diabetic Vitrectomy - a Pilot Study</brief_title>
  <acronym>RaDiVit</acronym>
  <official_title>A Prospective, Randomised Controlled Trial of Ranibizumab Pre-treatment in Diabetic Vitrectomy - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moorfields Eye Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Moorfields Eye Hospital NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of ranibizumab on patients undergoing vitrectomy surgery&#xD;
      for the complications of diabetic retinopathy.&#xD;
&#xD;
      Vitrectomy surgery can be difficult and bleeding after the operation can reduce vision for&#xD;
      patients. Our hypothesis is that injection into the eye of ranibizumab one week before&#xD;
      surgery will make the surgery easier, reduce complications and improve outcome.&#xD;
&#xD;
      In this trial, patients will be randomly allocated to receive either ranibizumab injection or&#xD;
      a placebo injection of saline. Neither the patient, their surgeon, nor the study&#xD;
      investigators will know which they have received so that a fair comparison can be made.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The RaDiVit study is a pilot randomised controlled trial to evaluate the effect of&#xD;
      ranibizumab as an adjunct to diabetic vitrectomy surgery.&#xD;
&#xD;
      Patients with complications of proliferative diabetic retinopathy who require vitrectomy&#xD;
      surgery will be recruited to this study. Baseline tests will be performed, including&#xD;
      refracted visual acuity, B-scan ultrasound, OCT scanning, colour fundus photography and&#xD;
      fundus fluorescein angiography. Patients will be randomised 1:1 to receive either ranibizumab&#xD;
      intravitreal injection or saline subconjunctival injection.&#xD;
&#xD;
      One week later, surgery will be carried out. The baseline tests will be repeated on the day&#xD;
      of surgery to examine for any discernible difference between the two groups one week after&#xD;
      treatment. Surgery will be video recorded and detailed assessments of the operative details&#xD;
      carried out.&#xD;
&#xD;
      A vitreous sample and a paired serum sample will be taken at the time of surgery to compare&#xD;
      levels of ranibizumab and related cytokines.&#xD;
&#xD;
      Follow up visits will take place at six and twelve weeks. Assessments at that point will&#xD;
      include:&#xD;
&#xD;
        -  visual acuity&#xD;
&#xD;
        -  OCT scan&#xD;
&#xD;
        -  colour fundus photography and fundus fluorescein angiography&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2011</start_date>
  <completion_date type="Actual">March 12, 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>12 weeks post-op</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ease of performing vitrectomy surgery</measure>
    <time_frame>One week post injection</time_frame>
    <description>Assessed by surgical scoring systems and counting tool usage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post-operative vitreous haemorrhage</measure>
    <time_frame>6 weeks post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of retinal neovascularisation</measure>
    <time_frame>6 weeks post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of tractional retinal detachment</measure>
    <time_frame>1 week post-injection</time_frame>
    <description>Assessed by serial B-scan ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of macular perfusion</measure>
    <time_frame>12 weeks post-op</time_frame>
    <description>Assessed by fundus fluorescein angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitreous and serum levels of ranibizumab and related cytokines</measure>
    <time_frame>One week post-injection</time_frame>
    <description>Samples to be taken on day of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post-operative vitreous haemorrhage</measure>
    <time_frame>12 weeks post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of retinal neovascularisation</measure>
    <time_frame>12 weeks post-op</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <condition>Retinal Neovascularisation</condition>
  <arm_group>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Intravitreal injection of ranibizumab, 0.5mg in 0.05ml</description>
    <arm_group_label>Ranibizumab</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Subconjunctival injection of 0.05ml saline 0.9% w/v</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of either sex aged 18 years or over&#xD;
&#xD;
          2. Diagnosis of diabetes mellitus (type 1 or type 2). Any one of the following will be&#xD;
             considered to be sufficient evidence that diabetes is present:&#xD;
&#xD;
               -  Current regular use of insulin for the treatment of diabetes&#xD;
&#xD;
               -  Current regular use of oral anti-hyperglycaemic agents for the treatment of&#xD;
                  diabetes&#xD;
&#xD;
               -  Documented diabetes by ADA and/or WHO criteria (see Procedures Manual for&#xD;
                  Diagnosis of Diabetes)&#xD;
&#xD;
          3. Proliferative diabetic retinopathy with complications of this requiring vitrectomy&#xD;
             surgery with anticipated delamination of pre-retinal fibrovascular complexes&#xD;
&#xD;
          4. Ability to return for study visits&#xD;
&#xD;
          5. Ability to give informed consent throughout the duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity to the active substance or to any of the excipients.&#xD;
&#xD;
          2. Active or suspected ocular or periocular infections.&#xD;
&#xD;
          3. Vitreous haemorrhage presumed to be caused by vitreous traction on a single, focal&#xD;
             point of vitreoretinal attachment&#xD;
&#xD;
          4. Cataract that, in the opinion of the investigators, would be significant enough to&#xD;
             impair the view during surgery&#xD;
&#xD;
          5. Active severe intraocular inflammation&#xD;
&#xD;
          6. Previous vitrectomy surgery on study eye&#xD;
&#xD;
          7. Vision in fellow eye 3/60 or worse&#xD;
&#xD;
          8. Uncontrolled glaucoma&#xD;
&#xD;
          9. History of stroke, peripheral vascular disease, angina or myocardial infarction within&#xD;
             six months prior to randomisation&#xD;
&#xD;
         10. Systemic anti-VEGF or pro-VEGF treatment within 3 months prior to randomisation&#xD;
&#xD;
         11. Pregnancy or lactation&#xD;
&#xD;
         12. Male or female unwilling to use contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James W Bainbridge, MA PhD FRCOphth</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moorfields Eye Hospital and UCL Institute of Ophthalmology Biomedical Research Centre for Ophthalmology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 1, 2011</study_first_submitted>
  <study_first_submitted_qc>March 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2011</study_first_posted>
  <last_update_submitted>September 7, 2020</last_update_submitted>
  <last_update_submitted_qc>September 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Diabetes Complications</keyword>
  <keyword>Retinal Diseases</keyword>
  <keyword>Endothelial Growth Factors</keyword>
  <keyword>Monoclonal Antibodies</keyword>
  <keyword>Ranibizumab</keyword>
  <keyword>Vitrectomy</keyword>
  <keyword>Vitreoretinal Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Retinal Neovascularization</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

